Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818232 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01818232: Completed Phase 1 study, sponsored by Lexicon Pharmaceuticals.
NCT01818232 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01818232, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg \[14C\]LX4211 to healthy male subjects
Interventions
- DRUG [14C]-LX4211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
What the finished NCT01818232 record still lists
NCT01818232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-LX4211 is the first listed.
NCT01818232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01818232 about?
NCT01818232 is a clinical study titled "Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects". This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg \[14C\]LX4211 to healthy male subjects
What is the current status of trial NCT01818232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01818232?
The interventions under investigation include: [14C]-LX4211 (DRUG).
Who is sponsoring clinical trial NCT01818232?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01818232's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia